The Brazilian group Interdisciplinary AIDS Association, or ABIA, has joined Indian patient advocacy groups to oppose a patent form for Gilead Science's antiretroviral drug Tenofovir, saying that the patent would have a direct impact on Brazil's ability to produce and access affordable generic versions of the drug, India's mtier test reports. Opponents of the patent say that the drug consists of a until now known jumble and, therefore, cannot be patented under India's Patents Act.

More: - Read More